Astrana Health (ASTH) AI Stock Analysis

• Market Cap: $1.67B
• Dividend Yield: N/A
• Average Volume (3M): 335.27K
• Price to Earnings (P/E): 132.6
• Beta (1Y): 1.17
• Revenue Growth: 68.17%
• EPS Growth: -85.23%
• Country: US
• Employees: 1,900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.01
• Shares Outstanding: 49,927,530
• 10 Day Avg. Volume: 398,368
• 30 Day Avg. Volume: 335,270
• PEG Ratio: -1.16
• Price to Book (P/B): 2.11
• Price to Sales (P/S): 0.74
• P/FCF Ratio: 34.04
• Enterprise Value/Market Cap: 0.00
• Enterprise Value/Revenue: 0.00
• Enterprise Value/Gross Profit: 0.00
• Enterprise Value/Ebitda: 0.00
• 1Y Price Target: $43.50
• Price Target Upside: 31.86% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 61 Neutral
• Price Target: $27.00 ▼(-18.16% Downside)

Astrana Health's overall stock score is driven by strong financial performance and positive earnings call highlights, including significant revenue growth and strategic partnerships. However, the high P/E ratio and bearish technical indicators present notable risks. Addressing operational efficiency and valuation concerns could enhance the stock's attractiveness.

Positive Factors

Revenue Growth

The significant revenue growth reflects strong market demand and successful integration of acquisitions, indicating robust business expansion and market penetration.

Cash Generation

Strong cash generation enhances Astrana Health's financial flexibility, enabling reinvestment in growth initiatives and providing a buffer against economic uncertainties.

Strategic Partnerships

Strategic partnerships enhance market presence and service offerings, driving long-term growth and competitive advantage in the healthcare sector.

Negative Factors

Profitability Margins

Eroding profitability margins suggest cost pressures and operational inefficiencies, which could hinder sustainable long-term profitability if not addressed.

Contract Transition Delays

Delays in contract transitions may lead to revenue and profit shortfalls, affecting financial performance and strategic execution in the near term.

Medicaid Headwinds

Regulatory challenges in Medicaid could impact membership and rates, posing risks to revenue stability and growth in these segments.

Astrana Health Business Overview & Revenue Model

Company Description

Astrana Health (ASTH) is a healthcare technology company focused on providing innovative solutions that enhance patient care and streamline healthcare operations. Operating primarily in the health tech sector, Astrana Health develops a suite of digital health products, including telehealth platforms, electronic health record (EHR) systems, and data analytics tools designed to improve healthcare delivery and outcomes across various medical specialties.

How the Company Makes Money

Astrana Health generates revenue through multiple streams, primarily by offering subscription-based services for its telehealth and EHR platforms to healthcare providers and institutions. Additionally, the company earns income through licensing fees for its analytics tools and by providing consulting services that help healthcare organizations optimize their operations. Significant partnerships with healthcare systems and insurance providers enhance its market reach and create bundled service offerings, further contributing to its revenue. The company may also explore additional income through strategic collaborations and pilot programs that validate its technologies for broader adoption.

Astrana Health Financial Statement Overview

Summary

Astrana Health exhibits a strong growth trajectory with improving cash flow metrics and a healthier balance sheet. However, declining profitability margins and reduced return on equity highlight areas for improvement. The company is well-positioned in terms of leverage and cash generation, but needs to address operational efficiency to enhance profitability.

Income Statement

Astrana Health has shown a consistent revenue growth trend, with a notable 7.49% increase in the TTM period. However, profitability margins such as the gross profit margin and net profit margin have declined over time, indicating potential cost pressures. The EBIT and EBITDA margins have also decreased, suggesting challenges in operational efficiency.

Balance Sheet

The company's debt-to-equity ratio has significantly improved in the TTM period, indicating a stronger balance sheet with reduced leverage. However, the return on equity has decreased, reflecting lower profitability relative to equity. The equity ratio remains stable, showcasing a solid capital structure.

Cash Flow

Astrana Health has demonstrated impressive free cash flow growth of 126.75% in the TTM period, indicating strong cash generation capabilities. The operating cash flow to net income ratio has improved, suggesting better cash conversion. However, the free cash flow to net income ratio remains high, indicating reliance on cash flow for profitability.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.55B	2.03B	1.39B	1.14B	773.91M	370.25M
Gross Profit	205.41M	271.39M	214.96M	199.48M	177.77M	21.70M
EBITDA	50.24M	141.84M	123.69M	112.08M	100.66M	29.74M
Net Income	10.24M	43.15M	60.72M	45.17M	68.92M	-23.75M
Balance Sheet
Total Assets	2.24B	1.35B	933.36M	966.21M	867.36M	817.49M
Cash, Cash Equivalents and Short-Term Investments	463.45M	290.83M	296.31M	293.59M	286.51M	261.17M
Total Debt	85.22M	471.84M	321.01M	229.36M	200.98M	260.56M
Total Liabilities	1.68B	840.73M	522.59M	407.67M	356.72M	372.34M
Stockholders Equity	775.54M	712.72M	614.22M	542.56M	448.17M	330.82M
Cash Flow
Free Cash Flow	93.89M	44.17M	39.70M	59.19M	51.11M	45.00M
Operating Cash Flow	106.53M	52.20M	68.23M	82.13M	70.33M	46.16M
Investing Cash Flow	-571.36M	-192.40M	-65.52M	-7.11M	16.54M	95.49M
Financing Cash Flow	580.39M	135.04M	3.42M	-20.09M	-47.75M	-51.70M

Astrana Health Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 32.99
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ASTH, the sentiment is Negative. The current price of 32.99 is above the 20-day moving average (MA) of 32.02, above the 50-day MA of 30.44, and above the 200-day MA of 29.46, indicating a bearish trend. The MACD of 0.24 indicates Positive momentum. The RSI at 29.90 is Positive, neither overbought nor oversold. The STOCH value of 41.46 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ASTH.

Astrana Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MD	73 Outperform	$1.86B	11.52	19.98%	―	-4.21%	―
HCSG	72 Outperform	$1.27B	32.35	8.07%	―	6.26%	-19.33%
SEM	67 Neutral	$1.66B	15.35	5.57%	1.79%	-22.96%	-59.35%
ASTH	61 Neutral	$1.67B	132.65	1.29%	―	68.17%	-85.23%
USPH	61 Neutral	$1.34B	37.04	7.30%	2.03%	17.50%	154.28%
AVAH	54 Neutral	$1.92B	114.76	―	―	15.48%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Astrana Health Corporate Events

Astrana Health Inc. Reports Strong Q3 Earnings Amid Growth

Astrana Health Inc.’s recent earnings call painted a largely optimistic picture, underscored by significant revenue and EBITDA growth, the successful integration of Prospect Health, and advancements in technology. While the company faces challenges such as delays in transitioning to full risk contracts and potential Medicaid headwinds, the overall sentiment remained positive, buoyed by strong financial performance and strategic partnerships.

Astrana Health Reports Strong Revenue Growth in Q3 2025

Astrana Health, Inc. is a provider-centric, technology-powered healthcare company that focuses on delivering accessible, high-quality, and high-value care through its scalable care delivery infrastructure and proprietary technology platform. The company operates in the healthcare sector, supporting over 20,000 providers and 1.6 million patients in value-based care arrangements.

Astrana Health Reports Strong Q3 Revenue Growth

On November 6, 2025, Astrana Health announced its third-quarter financial results, reporting a 100% year-over-year increase in total revenue to $956 million, with adjusted EBITDA reaching $68.5 million. The company successfully integrated Prospect Health, exceeding performance expectations and expanding its market reach. Astrana also updated its full-year 2025 guidance to reflect delays in full-risk contract transitions, which are expected to complete in early 2026. The strategic partnerships and acquisitions are set to enhance Astrana’s position in the healthcare industry, focusing on coordinated, high-quality care delivery.

The most recent analyst rating on (ASTH) stock is a Buy with a $37.00 price target. To see the full list of analyst forecasts on Astrana Health stock, see the ASTH Stock Forecast page.

Astrana Health Inc. Shines in Q2 2025 Earnings Call

Astrana Health Inc. recently held its Q2 2025 earnings call, showcasing a robust financial performance and strategic growth despite facing challenges in Medicaid and health insurance exchanges. The sentiment was overwhelmingly positive, with the company demonstrating confidence in its ability to navigate these hurdles effectively.

Astrana Health Inc. Reports Strong Q2 2025 Results

Astrana Health Inc. is a technology-driven healthcare company focused on providing high-quality, accessible care through its provider-centric model, operating primarily in the healthcare sector.